Caribou Biosciences

IPO

Developing Sophisticated Allogeneic Cell Therapies

Caribou Biosciences is a biotech company in Berkeley, United States, founded in 2011. It has raised $181.0M across 4 rounds, most recently a $25.0M Corporate Round in July 2023.

Employees
51–200
Founded
2011
Business Model
B2B
Total Funding
$181.0M
Last Round
$25.0M Corporate RoundJul 2023
Rounds
4
Type
Public

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 4 funding rounds and 7 investors for this company. to use credits for reveals, or explore the API.

About

Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. Its proprietary Cas12a chRDNA (CRISPR hybrid RNA-DNA) genome-editing platform enables superior precision for complex multiplex editing, including gene knockout and insertion. Caribou is advancing CB-010 and CB-011 as off-the-shelf allogeneic CAR-T cell therapies targeting hematologic malignancies.

Funding & Exit History

Data from Indexed.vcUpdated
Corporate RoundCorporate RoundJul 2023
$25.0M

4 more events

  • IPO2021
  • Series C20213 investors
  • Series B2016

Funding: Series A through Corporate Round. Amounts, valuations, and investors where available.

Investors

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

  • DevOps ×1
  • Frontend ×1
  • Marketing & SEO ×1

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Companies in related industries

Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech
Series DTotal funding$1.4BJun 2020
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Biotech
Series ATotal funding$3.0BJan 2022
BridgeBioIPO

BridgeBio develops treatments for genetic conditions through autonomous condition-focused teams s...

San Francisco Bay Area, United States201–500Biotech
Growth EquityTotal funding$2.7BJul 2026
AsymchemIPO

Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...

Tianjin, China5001–10000Biotech
Private EquityTotal funding$2.3BFeb 2020
Calico

Calico researches human aging using advanced technologies and model systems, applying that knowle...

South San Francisco, United States201–500Biotech
Corporate RoundTotal funding$2.3BJun 2018
Paratek PharmaceuticalsAcquired

Paratek Pharmaceuticals develops and delivers innovative treatments for serious infectious diseas...

Boston, United States201–500Biotech
ConvertibleTotal funding$1.8BApr 2018

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Caribou Biosciences on Indexed.vc
<a href="https://indexed.vc/companies/caribou-biosciences"><img src="https://indexed.vc/api/badge/company/caribou-biosciences" alt="Caribou Biosciences on Indexed.vc" width="260" height="76" /></a>